Role of posaconazole in the treatment of oropharyngeal candidiasis

Figures & data

Figure 1 Structural formula of posaconazole.

Table 1 Evidence for use of posaconazole in HIV patients with OPC and/or esophageal candidiasis

Study	Study design	Study population	Posaconazole	Fluconazole	Results
Skiest et al^Citation11	Phase III, open-label	OPC or EC with refractory disease to fluconazole, 199 patients	400 mg bid for 3 days, then 400 mg qd for 25 days or 400 mg bid for 28 days		75% clinical response
Vasquez et al^Citation22	Randomized, evaluator-blinded	OPC, 350 patients	200 mg first day, then 100 mg qd for 13 days	200 mg first day, then 100 mg qd for 13 days	Posaconazole as effective as fluconazole, CI 95%

Abbreviations: EC, esophageal candidiasis; OPC, oropharyngeal candidiasis; qd, once daily, CI, confidence interval.

SkiestDJVazquezJAAnsteadGMPosaconazole for the treatment of azole refractory oropharyngeal and esophageal candidiasis in subjects with HIV infectionsClin Infect Dis20074460761417243069

 PubMed Web of Science ®Google Scholar

VasquezJASkiestDJNietoLA multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDSClin Infect Dis2006421179118616575739

 PubMed Web of Science ®Google Scholar